Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the JDRF lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event was designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > Knowledge & support > About type 1 diabetes > Treatments for type 1 diabetes > Biosimilars
‘Biosimilar’ is a term used to describe a medicine that is designed to be very similar to existing ‘biologic’ medicines. All insulins are biologic medicines. Some of the analogue insulins above will soon come off patent which means other companies are then free to produce ‘biosimilar’ versions of them. You can read more about biosimilars in our FAQ document.
When a biologic drug comes off patent, the door is open for other companies to produce similar drugs – biosimilars. This is a similar process to when small molecule drugs come off patent and companies start to produce ‘generic’ versions of the same drug. However, because biologic drugs are more complex, producing identical ‘generic’ biologic drugs is impossible, which means that the new term biosimilar is used instead.
‘Biosimilar’ versions of different sorts of insulin are likely to become available soon, as the exclusive patents on some forms of insulin are about to expire.
It means that your doctor has more types of insulin to offer you. You or your doctor may think it is a good idea to try a new biosimilar insulin. Doctors should always prescribe insulins by their brand name to ensure that the correct insulin is given – biosimilars are no exception. There should be no clinically significant differences between the original insulin and its biosimilar, and the drugs will only be approved by regulators on this basis. As with any change in your treatment regimen, it should be something that you and your health team agree on, and you will need to pay especially close attention to your glucose levels for a few weeks to make sure the change is not disrupting your glucose control. If you experience any difficulties using the new insulin, your doctor can switch your prescription back to your usual insulin.
No. This area of research is well-funded by the pharmaceutical industry, so we can prioritise funding other areas of type 1 diabetes research.
The Association of the British Pharmaceutic Industry a has produced a helpful guide to biologic and biosimiliar medicines.
Find out about all about the different types of insulin and how to get it into your body.
Around 90% of people with type 1 in the UK inject their insulin through multiple daily injections. Learn more about injections, pens and needles.
Islet transplants take insulin-producing islets from someone who doesn’t have type 1 diabetes and put them into someone who does.